Omalizumab has shown efficacy as an adjuvant to multi-food oral immunotherapy (mOIT). However, there is no evidence of the minimum dose necessary for optimal outcome.
R. Sharon Chinthrajah合作论文数Division of Allergy, Immunology, & Rheumatology, Department of Pediatrics, Stanford University4
A. Long合作论文数3
Sandra Andorf合作论文数3
Kari C Nadeau合作论文数Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University;Allergy, Extreme Weather, and Exposomics Lab, Harvard T.H. Chan School of Public Health, Harvard University3A. Assa'Ad合作论文数2M. Woch合作论文数2D. Tupa合作论文数2S. Tilles合作论文数2Sayantani B. Sindher合作论文数2J. Tam合作论文数2Pongracic Jacqueline A合作论文数2
Stephen J. Galli合作论文数Department of Pathology, School of Medicine, Stanford University2Jonathan M. Spergel合作论文数2M LIERL合作论文数1D. Petroni合作论文数1S. Jiang合作论文数Department of Medicine, Santa Clara Valley Medical Center1S. Sicherer合作论文数1S. Cao合作论文数1
Melanie M Makhija合作论文数Allergy and Immunology, Department of Pediatrics, Feinberg School of Medicine, Northwestern University1
Rachel G. Robison合作论文数Department of Pediatrics, Vanderbilt University Medical Center1
Hugh A Sampson合作论文数Icahn School of Medicine at Mount Sinai;Jaffe Food Allergy Institute1K. Fast合作论文数1
Maria Garcia-Lloret合作论文数the David Geffen School of Medicine, University of California at Los Angeles1Antonella Cianferoni合作论文数Both authors contributed equally to this work1
Teh Yu Tan合作论文数Department of Mechanical Engineering and Materials Science, Duke University1
